Axitinib in the treatment of metastatic renal cell carcinoma

Future Oncology

Volumn 7, Issue 11, 2011, Pages 1247-1253

  Ho, Thai H ^a   Jonasch, Eric ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AG 013736; angiogenesis; AXIS; axitinib; renal cell carcinoma; targeted therapy; VEGF

Indexed keywords

AXITINIB; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; KETOCONAZOLE; PHENYTOIN; RIFAMPICIN; VASCULOTROPIN RECEPTOR;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CAUCASIAN; DEHYDRATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSPHONIA; EPISTAXIS; FATIGUE; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; HYPERTENSION; HYPOTHYROIDISM; JAPANESE; KIDNEY CARCINOMA; LUNG HEMORRHAGE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYALGIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 80455158267     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.107     Document Type: Article

References (23)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61, 212-236 (2011).
2. Rugo HS, Herbst RS, Liu G et al. Phase I trial of the oral antiangiogenesis agent AG 013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 23, 5474-5483 (2005).
3. Pithavala YK, Tortorici M, Toh M et al. Effect of rifampin on the pharmacokinetics of axitinib (AG 013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother. Pharmacol. 65, 563-570 (2010).
4. Pithavala YK, Tong W, Mount J et al. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest. New Drugs doi: 101007/s10637-010-9511-6 (2010) (Epub ahead of print).
5. Hu-Lowe DD, Zou HY, Grazzini ML et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG 013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin. Cancer Res. 14, 7272-7283 (2008).
6. Liu G, Rugo HS, Wilding G et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG 013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a Phase I study. J. Clin. Oncol. 23, 5464-5473 (2005).
7. Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a Phase II study. Lancet Oncol. 8, 975-984 (2007). (Pubitemid 47629888)
8. Rini BI, Wilding G, Hudes G et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 27, 4462-4468 (2009).
9. Rini BI, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of Phase III AXIS trial. Presented at: 47th ASCO Annual Meeting (2011).Chicago, IL, USA, 4-8 June 2011
10. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur. J. Cancer 42, 3127-3139 (2006). (Pubitemid 44869016)
11. Feldman DR, Baum MS, Ginsberg MS et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1432-1439 (2009).
12. Rini BI, Garcia JA, Cooney MM et al. A Phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin. Cancer Res. 15, 6277-6283 (2009).
13. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372, 449-456 (2008).
14. Yao M, Tabuchi H, Nagashima Y et al. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J. Pathol. 205, 377-387 (2005). (Pubitemid 40253927)
15. Brannon AR, Reddy A, Seiler M et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 1, 152-163 (2010).
16. Gordan JD, Lal P, Dondeti VR et al. HIF a effects on c Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14, 435-446 (2008).
17. Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542 (2011).
18. Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363 (2010).
19. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337 (2003). (Pubitemid 36109749)
20. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004). (Pubitemid 39331023)
21. Harris PA, Boloor A, Cheung M et al. Discovery of 5-[[4-[(2,3-dimethyl- 2H-indazol-6-yl)methylamino]-2-pyrimidinyl] amino]-2 m ethyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem. 51, 4632-4640 (2008).
22. Podar K, Tonon G, Sattler M et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl Acad. Sci. USA 103, 19478-19483 (2006). (Pubitemid 46026056)
23. Jonasch E, Bair A, Chen, Y, Rini BI. Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC).Presented at: 46th ASCO Annual Meeting (2010).Chicago, IL, USA, 4-8 June 2010